Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is biotech subprime pharma? Too much Phase II, not enough Phase III

This article was originally published in Scrip

Executive Summary

With big pharma facing a fall in revenues associated with the patent expiries of key blockbuster drugs coupled with a drying of its own R&D pipelines, it may be surprising that more biotech asset accumulation deals are not consummated. Closer examination of the pipelines of the biotech industry throws some light on why deal making has remained at a subdued rate.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC013649

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel